MedTrace Logo

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

NCT00685750 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2019-06-20

Study results available
· View outcomes & findings →

Summary

This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma. The data obtained in this study will be used to guide future development of immunotherapies for melanoma or NSCLC patients. Moreover, the analyses will contribute to definition of markers potentially predictive of clinical response to specific anticancer therapies.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

PROCEDURE

Collection of tumor and blood samples

Samples will be collected before and after standard treatment

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-28
Primary Completion
2013-12-17
Completion
2013-12-17

Countries

  • United States
  • France
  • Germany
  • Italy
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685750 on ClinicalTrials.gov